ZSX Medical, LLC

ZSX Medical makes the hardest part of surgery easy with a simple, cost-saving, and effective means to close internal surgical incisions in hysterectomy.

  • Stage Full Product Ready
  • Industry Medical Devices and Equipment
  • Location Philadelphia, PA, US
  • Currency USD
  • Founded June 2009
  • Employees 4
  • Incorporation Type LLC
  • Website zipstitch.com

Company Summary

ZSX Medical is focused on developing products to help surgeons do their work more effectively and easily. We believe that making surgeons' work easier will help patients, save hospitals money, and reduce overall healthcare costs.

Our lead product, Zip-stitch, is currently being tested in real clinical use. Zip-stitch is the lead application in a platform of wound closure devices intended to address identified needs in surgical closure.

Team

  • President & CEO

    Dan Mazzucco, Ph.D., has been in the medical device industry for 20+ years. Prior to joining ZSX Medical, Dr. Mazzucco directed manufacturing, preclinical, clinical, and regulatory development at Aqumen Biopharmaceuticals, a Japanese ophthalmic biotechnology startup. Dr. Mazzucco earned a doctorate in medical and mechanical engineering from Harvard Medical School and MIT in the Division of Health Sciences and Technology.

  • Chief Technology Officer

    Anthony Bellezza is a serial entrepreneur with experience in technology development and business management in early-stage medical device companies. He has 15+ years of experience in identifying, financing, and introducing early or seed-stage technologies to the marketplace. He is the Principal Investigator on seven state and federal grants, including multiple Phase I and Phase II SBIR grants from NSF.

  • John Crombie
    VP Product Development

    John Crombie leads engineering and product development. Mr. Crombie has 30 years of experience as a successful product & portfolio developer for diverse markets (surgical, diagnostic, therapeutic, and consumer) and diverse specialties, including with Pfizer, Ethicon, and J&J. Among 70 issued patents and across seven companies, Mr. Crombie has maintained a 70% commercialization rate of intellectual property.

Advisors

  • Saul Ewing, LLP
    Lawyer
    Unconfirmed
    Jennifer Anderson, LLC
    Accountant
    Unconfirmed
    Broad Street Angels
    Unconfirmed

Previous Investors

  • Feta Med/Founders
    Unconfirmed
    Kereitsu Forum Mid-atlantic
    Unconfirmed
    Rowan Innovation Venture Fund
    Unconfirmed
  • Keiretsu Forum Southeast
    Unconfirmed
    Keiretsu Forum Pacific Northwest
    Unconfirmed
    Various other angel investors
    Unconfirmed

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free